Interleukin 24 gene therapy + radiotherapy in patients with locally advanced, unresectable, head and neck cancer.

Trial Profile

Interleukin 24 gene therapy + radiotherapy in patients with locally advanced, unresectable, head and neck cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2014

At a glance

  • Drugs Interleukin 24 gene therapy-MultiVir (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors MultiVir
  • Most Recent Events

    • 03 Mar 2014 New trial record
    • 14 Feb 2014 Top-line results presented at the Leerink Global Healthcare conference reported in a MultiVir media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top